Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Elliott

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
JMIR Formative Research|January 5, 2024
Novel Web-Based Drop-In Mindfulness Sessions (Pause-4-Providers) to Enhance Well-Being Among Health Care Workers During the COVID-19 Pandemic: Descriptive and Qualitative StudyMary Elliott, Camille Khallouf, Jennifer Hirsch, et al.
Journal of the American Heart Association|March 3, 2020
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 StudiesPeter P Toth, Steven R Jones, Maria Laura Monsalvo, et al.
The Lancet. Diabetes & Endocrinology|February 13, 2016
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient dataNaveed Sattar, David Preiss, Jennifer G Robinson, et al.
Springerplus|April 12, 2016
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingRicardo Dent, Raju Joshi, C Stephen Djedjos, et al.
Diabetologia|April 7, 2019
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING studyRobert S Rosenson, Martha L Daviglus, Yehuda Handelsman, et al.
Current Oncology Reports|June 23, 2020
Transitioning to a New Normal in the Post-COVID EraDi M Jiang, Alejandro Berlin, Lesley Moody, et al.
The American Journal of Cardiology|August 29, 2017
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes MellitusNaveed Sattar, Peter P Toth, Dirk J Blom, et al.
Plos Neglected Tropical Diseases|July 1, 2009
Risk factors for helminth, malaria, and HIV infection in pregnancy in Entebbe, UgandaPatrick William Woodburn, Lawrence Muhangi, Stephen Hillier, et al.
The American Journal of Cardiology|December 10, 2017
Effect of Evolocumab on Lipoprotein ParticlesPeter P Toth, Naveed Sattar, Dirk J Blom, et al.
Diabetes, Obesity & Metabolism|September 14, 2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndromeDirk J Blom, Michael J Koren, Eli Roth, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
JMIR Formative Research|January 5, 2024
Novel Web-Based Drop-In Mindfulness Sessions (Pause-4-Providers) to Enhance Well-Being Among Health Care Workers During the COVID-19 Pandemic: Descriptive and Qualitative StudyMary Elliott, Camille Khallouf, Jennifer Hirsch, et al.
Journal of the American Heart Association|March 3, 2020
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 StudiesPeter P Toth, Steven R Jones, Maria Laura Monsalvo, et al.
The Lancet. Diabetes & Endocrinology|February 13, 2016
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient dataNaveed Sattar, David Preiss, Jennifer G Robinson, et al.
Springerplus|April 12, 2016
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingRicardo Dent, Raju Joshi, C Stephen Djedjos, et al.
Diabetologia|April 7, 2019
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING studyRobert S Rosenson, Martha L Daviglus, Yehuda Handelsman, et al.
Current Oncology Reports|June 23, 2020
Transitioning to a New Normal in the Post-COVID EraDi M Jiang, Alejandro Berlin, Lesley Moody, et al.
The American Journal of Cardiology|August 29, 2017
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes MellitusNaveed Sattar, Peter P Toth, Dirk J Blom, et al.
Plos Neglected Tropical Diseases|July 1, 2009
Risk factors for helminth, malaria, and HIV infection in pregnancy in Entebbe, UgandaPatrick William Woodburn, Lawrence Muhangi, Stephen Hillier, et al.
The American Journal of Cardiology|December 10, 2017
Effect of Evolocumab on Lipoprotein ParticlesPeter P Toth, Naveed Sattar, Dirk J Blom, et al.
Diabetes, Obesity & Metabolism|September 14, 2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndromeDirk J Blom, Michael J Koren, Eli Roth, et al.
Pageof 3